IRIS
CAGNETTA, ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.864
AS - Asia 28
SA - Sud America 3
Totale 5.895
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.864
CN - Cina 25
SG - Singapore 3
BR - Brasile 2
AR - Argentina 1
Totale 5.895
Salva come PNG Salva come JPEG
Città #
Genova 3.185
Genoa 1.821
Rapallo 491
Vado Ligure 355
Beijing 14
Bordighera 8
Perugia 3
Singapore 2
Santa Sylvina 1
Saquarema 1
Ubá 1
Totale 5.882
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 219
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 209
APO866 activity in hematologic malignancies: a preclinical in vitro study. 204
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 196
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 193
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 176
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 165
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 165
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 165
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 163
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 158
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 153
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 151
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 149
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 147
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 145
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 143
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 138
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 137
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 135
New insights into biology of chronic myeloid leukemia: implications in therapy. 133
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 131
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 131
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 128
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 126
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 124
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 122
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 122
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 122
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 120
MiR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 119
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 118
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 117
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 110
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 105
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 101
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 92
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 89
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 86
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 83
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 83
The non-coding RNA landscape of plasma cell dyscrasias 62
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 58
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma 50
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma 49
Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies 48
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 32
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma 31
Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses 5
Totale 6.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.074
article - articoli 20.074
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021350 0 0 0 32 51 27 27 39 31 55 51 37
2021/2022557 21 26 37 69 25 46 30 111 28 49 30 85
2022/2023610 68 69 3 73 99 89 6 37 85 12 65 4
2023/2024398 13 55 14 51 41 82 22 38 10 5 28 39
2024/20251.097 38 65 29 76 97 100 108 230 35 60 119 140
2025/2026620 263 69 116 172 0 0 0 0 0 0 0 0
Totale 6.008